Showing 28,461 - 28,480 results of 103,867 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( e ((fold decrease) OR (point decrease)) ))', query time: 1.05s Refine Results
  1. 28461
  2. 28462
  3. 28463

    Metabolome data of the discovery cohort. by Feng Gao (3548)

    Published 2025
    “…The results showed that compared with HC, five metabolites, including DL-stachydrine, D-(+)-pipecolinic acid, furazolidone, L-arginine and 5α-dihydrotestosterone glucuronide were significantly elevated and one metabolite, prenylcysteine, was significantly decreased in the serum of OC, and that the increase in L-arginine and the decrease in prenylcysteine led to impaired urea cycling and a high risk of developing atherosclerosis, respectively. …”
  4. 28464
  5. 28465
  6. 28466
  7. 28467
  8. 28468
  9. 28469
  10. 28470
  11. 28471
  12. 28472
  13. 28473
  14. 28474

    Molecular Insights into the Covalent Binding of Zoxamide to the β‑Tubulin of <i>Botrytis cinerea</i> by M. Andrés Velasco-Saavedra (17109105)

    Published 2023
    “…In agreement with experimental findings, alchemical free energy calculations showed that E198A and E198V mutations in <i>B. cinerea</i> β-tubulin have high sensitivity to (<i>R</i>)-ZOX, whereas the E198K mutation decreased its affinity. …”
  15. 28475
  16. 28476
  17. 28477
  18. 28478

    Baseline characteristics of the study population. by Haowen Wang (9294777)

    Published 2024
    “…Investigating climate factors with cancer incidence can provide valuable insights for prevention and future disease burden prediction. We conducted a population-based ecological study using data from the World Health Organization’s Cancer Incidence in Five Continents (CI5plus, 89 cancer registries from 1998 to 2012) and the Surveillance, Epidemiology, and End Results (SEER, 607 US counties from 2000 to 2018) Program. …”
  19. 28479
  20. 28480

    table_2.docx by Guzailiayi Maimaitijiang (5080394)

    Published 2018
    “…Therefore, the Vδ1/Vδ2 ratio might be a candidate biomarker for predicting disease severity in MS.…”